Victor Stone

President of 82VS Venture Studios and Head of Cell Therapies

2023

Alloy democratizes access to pre-competitive drug discovery technologies and services across six biologic modalities, and I am very excited to be taking a foundational role in building out the discovery services organization for cell therapy. The company already has an incredible footprint in antibodies and TCRs that I'm thrilled to expand on to empower the drug discovery community in their cell therapy endeavors. Company creation is also an exciting part of Alloy's business through 82VS, and I'm excited to partner with the team there around new companies to advance cell-therapy-based assets. We are still early in these efforts but please reach out if you are interested in exploring ways to collaborate and #makemedicinetogether.

President of 82VS Venture Studios and General Partner of 82VS Fund

2023

Consortia Director

2020

Japan VC Consortia is a consortia of over 20 Japanese biopharma (Pharma BD/CVC and Institutional VC) hosted by Shonan Health Innovation Park dedicated to actionable initiatives to advance the Japanese biotech ecosystem

Co-Founder

2021

Non Executive Director

2019

Largest small molecule platform in Japan, now a full-service pre-clinical CRO serving Japanese Biopharma clients. Spin out of R&D capabilities of Takeda Shonan Research Center including 240 high performing researchers

Senior Investment Director and Partner

2020 - 2023

Investments with focus in cell and gene therapies and new chemical space. Board Directorships summarized below. Board Observer roles include: Artisan Development Labs (Cas12a), Be BioPharma (Engineered B-Cell), Bridgene (PPI SMOL), RedPin Tx (AAV CNS), X-forest Tx (RNAi). Promoted to role in October 2021.

Non Executive Director

2021 - 2023

Non-viral gene delivery platform based on 3-DNA scaffold technology. Versatile platform enabling base construct of 18 points for engagers and gene cargo. Unprecedented signal-noise ratio with tissue specific targeting.

Non Executive Director

2022 - 2023

Synthetic Promoter developer enabling tissue specific expression in gene therapy and optimization of biologics manufacturing. Spinout from University of Sheffield, David C James and Adam Brown labs

Member Of The Supervisory Board

2021 - 2023

Mobile Diagnostics enabling point of care measurement of hematology biomarkers including Factor VIII, Von Willebrand Factor and Thrombin

Non Executive Director

2021 - 2022

Spinout from GammaDelta Therapeutics and supported by Abingworth and Takeda. Antibody approach to harness innate immune potential of gdT-cells for cancer immuno-therapy. Acquired by Takeda in April 2022